转载自企业官方网站。作者及内容来源：Crystal Bio Solutions.
Crystal Bio Solutions技术文章：CRO如何帮助降低抗体药物偶联物开发风险。 本文保留原始技术观点、参考资料和来源链接；全文按英文原文转载。
中文导读与摘要；下方正文为英文原文，并非完整中文译文。
本文为Crystal Bio Solutions发布的英文技术文章，以下按英文原文转载，尚未提供中文全文翻译。原始日期未由原站注明。
Originally published by Crystal Bio Solutions. Republished with company attribution. Original technical perspectives, references and source links are retained.
A skilled partner, such as CRO or a CRDMO, should provide the analytical depth, cross-functional expertise, and regulatory alignment required to advance an ADC program from early discovery to an IND submission with confidence.
Antibody–drug conjugate development requires close coordination across multiple scientific disciplines. Each component of the molecule behaves differently during circulation, degradation, and payload release, creating a level of complexity that is difficult to manage internally.
Most organizations cannot advance these programs alone and benefit greatly from partnering with a qualified CRO or CRDMO.
A strong partner provides more than individual assays. It offers troubleshooting support, process optimization, and the technical insight needed to understand the molecule and guide its progression with confidence. This support typically includes:
Without this integrated support, ADC programs risk delays, gaps in data continuity, and challenges during regulatory review.
Bioanalysis is at the center of every ADC program. It describes how the ADC moves through the body, how it releases its payload, and how long active species remain in circulation.
A CRO should develop and validate methods such as:
These data create a clear view of exposure, clearance, and payload release across species and time points. Read more about Strategies for Antibody–Drug Conjugates Bioanalysis
Biomarkers analysis connect ADC exposure to biological activity. They provide early signals of response, inform dose selection, and support proof of mechanism. A CRO helps identify and validate biomarkers that reflect both payload effects and immune responses.
Examples of CRO biomarker support include:
These data inform dose selection, patient stratification, and early proof of mechanism.
Chemistry, Manufacturing, and Controls (CMC) activities define the identity, purity, and stability of the ADC. Only highly experienced CROs can ensure that the product remains consistent across the entire development lifecycle, including all batches and study stages.
They protect the program from unexpected variability and provide the foundation for regulatory submissions. Key analytical elements include:
A robust CMC dataset demonstrates product reproducibility and supports regulatory submissions from IND to BLA.
Quantitative modeling is therefore essential for predicting clinical performance. ADCs follow complex pharmacokinetic pathways due to multiple elimination routes and controlled payload release, to predict success CROs should:
These quantitative frameworks strengthen dose rationale and support adaptive trial design.
Preparation for FDA or EMA review is one of the most demanding phases of ADC development. Consistent alignment across all scientific functions is essential.
The right CRO integrates data from bioanalysis, CMC analytics, biomarkers, and quantitative modeling to build a clear and coherent regulatory narrative. This work includes:
A coordinated approach ensures that regulators receive well supported and clearly presented evidence of product quality and performance.
Selecting the appropriate developmental partner is essential for the success of any ADC program. A strong partner should demonstrate:
At Crystal Bio Solutions, we have developed 300+ successful ADC projects, ensuring scientific continuity, regulatory readiness, and reliable progression from discovery to clinical development.
Read more about us